A prospective evaluation of Johnson & Johnson COVID-19 vaccine on glycemic biomarkers in type 2 diabetes mellitus in Ethiopia
The Johnson & Johnson COVID-19 vaccine was associated with short-term RBS fluctuations and a sustained increase in HbA1c levels in T2DM patients. These findings highlight the need for personalized glycemic monitoring post-vaccination. Despite these metabolic variations, the vaccine's protective role against severe COVID-19 outweighs transient glycemic disturbances. Incorporating vaccination efforts into comprehensive diabetes management is crucial, and additional studies are warranted to investigate the underlying biological mechanisms.
Authors
- Chala Kenenisa Edae (ORCID: https://orcid.org/0000-0002-1414-2742)
- Solomon Genet (ORCID: https://orcid.org/0000-0002-5433-0107)
- Abdisa Tufa Bedada (ORCID: https://orcid.org/0000-0003-2196-6835)
- Maria Degef Teklemariam
- Mesfin Bekele Tolesa
Institutions
- Addis Ababa Science and Technology University (ET)
- Addis Ababa University (ET)
- Adama Science and Technology University (ET)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1371/journal.pone.0340457
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00